Abstract: This invention provides isolated human antibodies and recombinant proteins comprising defined heavy chains and light chains, wherein the antibodies and recombinant proteins neutralize Andes Virus with defined IC50 values. This invention also provides related pharmaceutical compositions, treatment methods and kits.
Type:
Grant
Filed:
March 21, 2018
Date of Patent:
June 14, 2022
Assignees:
Ichor Biologies, LLC, Universidad De Concepcion
Inventors:
Maria Ines Barria, Jose Luis Garrido Ramirez, Felipe Edgardo Bravo Caceres
Abstract: Isolated peptides that include one or more antigenic sites of Zika virus (ZIKV) and methods of their use and production are disclosed. The peptides can be used, for example, to detect exposure of a subject to a flavivirus infection, such as a ZIKV infection.
Type:
Grant
Filed:
March 26, 2020
Date of Patent:
June 7, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
Type:
Grant
Filed:
July 17, 2019
Date of Patent:
May 31, 2022
Assignees:
Arizona Board of Regents, Conseju Superior De Investigaciones Cientificas, IPPOX Foundation
Inventors:
Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias El Haddad, James Tartaglia
Abstract: Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
May 24, 2022
Assignee:
The Penn State Research Foundation
Inventors:
Anthony Paul Schmitt, Phuong Tieu Schmitt, Greeshma Vivekananda Ray
Abstract: A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza maybe characterised by hypercytokinemia involving elevated levels of one or more pro-inflammatory cytokines. The p38 MAP kinase inhibitor may act to inhibit the release of such pro-inflammatory mediators from endothelial cells. In some embodiments, the p38 MAP kinase inhibitor may inhibit the release of IP 10 from endothelial cells, preferably in a dose-dependent manner.
Type:
Grant
Filed:
June 26, 2017
Date of Patent:
May 24, 2022
Assignee:
Orph Pharma IP Company Limited
Inventors:
Paul Andrew Whittaker, Neil Edward Torbett
Abstract: Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
May 17, 2022
Assignee:
Valneva Austria GmbH
Inventors:
Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
Abstract: The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.
Type:
Grant
Filed:
November 19, 2018
Date of Patent:
April 19, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.
Abstract: The present invention relates to novel influenza antigens, novel immunogenic or vaccine compositions, as well as to uses of and to methods for producing said antigens and compositions. In particular, the invention relates to recombinant forms of hemagglutinin (HA) and their use in vaccine compositions for the prevention of influenza virus infections.
Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
Type:
Grant
Filed:
April 16, 2020
Date of Patent:
March 22, 2022
Assignee:
ModernaTX, Inc.
Inventors:
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.
Type:
Grant
Filed:
April 30, 2020
Date of Patent:
March 22, 2022
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: The compositions and methods are described for generating an immune response to a tumor associated antigen such as MUC1. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a neoplasm expressing the tumor associated antigen in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat neoplasms and associated diseases.
Type:
Grant
Filed:
January 9, 2017
Date of Patent:
March 22, 2022
Assignee:
Geovax, Inc.
Inventors:
Harriet Robinson, Arban Domi, Michael Hellerstein, Farshad Guirakhoo, Nathanael Paul McCurley
Abstract: Nucleic acid based vaccine constructs encoding Lyssaviral antigens are useful in preventing and treating diseases. Self-amplifying RNA molecules encoding Lyssaviral antigens provide potent and long-lasting immunity.
Type:
Grant
Filed:
July 16, 2018
Date of Patent:
March 22, 2022
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Kathryn Hashey, Padma Malyala, Marcelo Samsa, Olga Slack, Dong Yu, Alan Stokes, Rashmi Jalah
Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
Abstract: The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.
Type:
Grant
Filed:
February 4, 2020
Date of Patent:
March 8, 2022
Assignee:
CureVac AG
Inventors:
Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Daniel Voss
Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein epitope from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
Type:
Grant
Filed:
May 23, 2018
Date of Patent:
February 8, 2022
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Ralph Baric, Matthew Begley, Douglas Widman, Aravinda Desilva, Usha Nivarthi, Boyd Yount, Ellen Young
Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
Type:
Grant
Filed:
April 21, 2020
Date of Patent:
February 1, 2022
Assignee:
ModernaTX, Inc.
Inventors:
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir